Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile

Phase 3negativeitepekimabinvestigational antibodyNegative

AI Analysis

Summary

Regeneron discontinued its Phase 3 uveitis study after an investigational antibody demonstrated an unfavorable risk/benefit profile. This marks another clinical setback for the company, following Phase 3 failures of itepekimab and a melanoma combination regimen.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

study discontinued after antibody showed unfavorable risk/benefit profile

Importance:7/10

Sentiment:

-0.90

clinical_setbackstudy_discontinuationuveitisPhase_3_failureunfavorable_safety_profile

Related Companies

$REGN

Read the original article

Published by BioSpace on August 18, 2026 11:23 AM

Read Original